About Mylin Biotech
Mylin Biotech is a Healthcare company. Biotech company focusing on gut-centric healthcare solutions and manufacturing. The company has 15 employees. Its Indian entity Mylin Biotech India Private Limited reported revenue of ₹8.10 Cr. Mylin Biotech offers products and services including ZAVETOX and Aminase. Its focus areas include Manufacturing, Contract Manufacturing, Biotech Products and Biotechnology.
Company details
It is noted that Mylin Biotech was established in 2012 as a research and innovation organization, where efforts are directed towards overcoming gut-mediated diseases through synbiotics, enzobiotics, and enzotein research. The companys commitment to gut health is evident in its exploration of axes like Gut-Kidney and Gut-Liver, with products undergoing rigorous testing and validation to address chronic conditions such as kidney disease and liver cirrhosis. Patent applications in multiple countries reflect the emphasis placed on quality and innovation in healthcare solutions, ensuring therapies are disseminated to professionals for patient benefit. Overall, a personalized approach to metabolic signatures is pursued to enhance well-being.
- Employees 15
- SectorsHealthcare
- Email••••••••
- Website mylinbiotech.com
- Social LinkedIn
- Legal Name Mylin Biotech India Pvt. Ltd
- Date of Incorporation 10 Dec, 2012
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹8.10 Cr
FY 2025 · +64% YoY
- Indian entity net profit₹1.06 Cr
FY 2025 · 13% margin
- Indian entity EBITDA₹1.81 Cr
FY 2025 · 22% margin
- Employee Count15
Associated legal entities of Mylin Biotech
Mylin Biotech operates through Mylin Biotech India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mylin Biotech India Private Limited CIN U73100KA2012PTC067115 | Active | 10 Dec 2012 | Bangalore, Karnataka | ₹8.1 Cr | 15 | 3 | View details |
Products & Services of Mylin Biotech
Mylin Biotech offers a comprehensive portfolio of products and services, including ZAVETOX and Aminase.
This product is utilized for managing gut dysbiosis and related chronic diseases through therapeutic combinations.
This service is employed for enhancing protein breakdown and assimilation in conditions like protein energy malnutrition.
Board of directors of Mylin Biotech India Private Limited (Mylin Biotech)
Mylin Biotech India Private Limited is the primary company behind Mylin Biotech. The board of Mylin Biotech India Private Limited currently have 3 directors; the longest-serving is Kavitha Prabakaran, appointed in 2012. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kavitha Prabakaran DIN 06422878 | Director | 10 Dec 2012 | 13 yrs 10 mo | Mylin Biotech India Private Limited |
| Ramasamy Ramajayam Pillai DIN 06422886 | Director | 10 Dec 2012 | 13 yrs 10 mo | Mylin Biotech India Private Limited |
| Pandurangan Prabhakran DIN 09598614 | Director | 09 May 2022 | 4 yrs 5 mo | Mylin Biotech India Private Limited |
Financials of Mylin Biotech
Figures of Mylin Biotech India Private Limited, the primary company behind Mylin Biotech, for FY 2025. Revenue was ₹8.10 Cr (+64% year on year). Net profit was ₹1.06 Cr (13% margin). EBITDA was ₹1.81 Cr (22% margin). Revenue has grown at a compounded annual rate of +62% over three years and +34% over five years.
- ₹8.10 CrRevenue · FY 2025 · +64% YoY
- ₹1.06 CrNet profit · 13% margin
- ₹1.81 CrEBITDA · 22% margin
- ₹3.4 LakhPaid-up capital
- 15Employees (provident fund records)
- +62%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Mylin Biotech India Private Limited are on its company page.
Detailed financial statements for Mylin Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mylin Biotech
Mylin Biotech has 15 employees.
The primary company behind Mylin Biotech, Mylin Biotech India Private Limited, reported revenue of ₹8.10 Cr for FY 2025, up 64% year on year.
It is noted that Mylin Biotech was established in 2012 as a research and innovation organization, where efforts are directed towards overcoming gut-mediated diseases through synbiotics, enzobiotics, and enzotein research. The companys commitment to gut health is evident in its exploration of axes like Gut-Kidney and Gut-Liver, with products undergoing rigorous testing and validation to address chronic conditions such as kidney disease and liver cirrhosis. Patent applications in multiple countries reflect the emphasis placed on quality and innovation in healthcare solutions, ensuring therapies are disseminated to professionals for patient benefit. Overall, a personalized approach to metabolic signatures is pursued to enhance well-being.
Mylin Biotech offers ZAVETOX and Aminase.
Mylin Biotech operates through Mylin Biotech India Private Limited.
The legal entities of Mylin Biotech currently have 3 directors, including Kavitha Prabakaran, Ramasamy Ramajayam Pillai, Pandurangan Prabhakran.